GRI Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Keller’s rating is based on the promising interim results from GRI Bio’s ongoing Phase 2a study, which suggest that their drug, GRI-0621, is effectively providing an anti-fibrotic effect in patients with idiopathic pulmonary fibrosis (IPF). The study has shown a favorable safety profile and extensive biomarker data that support the drug’s efficacy, which helps mitigate risks for future results.
Additionally, the trial is fully enrolled, and the company is on track to release topline results by the end of the year. Despite the short duration of the study so far, the absence of worsening lung function in patients is a positive sign. These factors, combined with the company’s financial position and ongoing favorable safety reviews, contribute to Keller’s Buy rating for GRI Bio.